Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals
Autor: | Asmaa Zaki El Naggar, Abdelnaser Abdelaty Gadallah, Khaled M. A. Elzorkany, Yassein S Yassein, Ahmed Zahran, Mahmoud Abdelaziz Kora, Aliaa Sabry Abdel Wahed, Hassan Zaghla, Abdallah Essa |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Daclatasvir Sofosbuvir business.industry Ribavirin Hepatitis C virus 030232 urology & nephrology Renal function 030204 cardiovascular system & hematology Ciclosporin medicine.disease_cause Gastroenterology Tacrolimus 03 medical and health sciences chemistry.chemical_compound Regimen 0302 clinical medicine chemistry Nephrology Internal medicine medicine business medicine.drug |
Zdroj: | International Journal of Nephrology and Renovascular Disease. 13:351-358 |
ISSN: | 1178-7058 |
Popis: | Purpose Direct acting antiviral agents (DAAs) have greatly improved the clearance of hepatitis C virus (HCV) infection. The effect of DAAs on renal function in post-liver transplant HCV-positive patients remains questionable, especially considering the possibility of drug interactions between immunosuppressants and DAAs. Patients and methods A retrospective observational study included 84 post-liver transplant patients with HCV infection. Patients were divided into two groups: group I received sofosbuvir plus ribavirin for 24 weeks, group II received sofosbuvir plus daclatasvir for 12 weeks. Laboratory data and eGFR were determined before, at the end, and 6 months after completion of treatment. Results The treatment was well tolerated with 100% sustained virologic response (SVR 12). There was no statistically significant difference between the two groups regarding clinical and laboratory data before treatment. Mean eGFR significantly reduced from 87.36 mL/min to 76.16 mL/min in group I (P=0.001). However, within 6 months after treatment, mean eGFR recovered to 81.51 mL/min, which was not significant when compared to baseline eGFR (P=0.09). Mean eGFR in group II showed non-significant change. There were no significant changes in immunosuppressive drug levels and eGFR in either group of patients, who received either ciclosporin or tacrolimus before and at the end of treatment. Conclusion DDAs in post-liver transplant patients with HCV infection were well tolerated and associated with stable renal function. Moreover, sofosbuvir plus daclatasvir regimen showed relatively better renal safety compared to sofosbuvir plus ribavirin. |
Databáze: | OpenAIRE |
Externí odkaz: |